Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial (2024)

Peer-Reviewed Study · Sanei ZS; Shahrahmani F; Khaleghi Manesh B; Hamidi-Alamdari D; Mehrad-Majd H; Mavaji Darban B; Mirdoosti SM; Seddigh-Shamsi M · August 29, 2024

Sanei ZS et al., 2024-08-29: Second Iranian randomised trial, in 122 hospitalised COVID-19 ARDS patients: oral methylene blue added to standard treatment produced significantly higher oxygen saturation over time and better APACHE II/SOFA-related outcomes than standard treatment alone.

A randomized clinical study was carried out on 122 hospitalized patients who had ARDS related to COVID-19.

Abstract

Sanei ZS et al., 2024-08-29: Second Iranian randomised trial, in 122 hospitalised COVID-19 ARDS patients: oral methylene blue added to standard treatment produced significantly higher oxygen saturation over time and better APACHE II/SOFA-related outcomes than standard treatment alone. Study type: randomised controlled trial, single centre, Mashhad University of Medical Sciences, Iran. N=122 (62 MB, 60 control); oral MB added to standard treatment. Outcomes: SpO2, CRP, LDH, APACHE II, SOFA at discharge, mortality at 1 and 3 months. Funder: Mashhad University of Medical Sciences grant 4000078. Ethics approval IR.MUMS.REC.1400.171. Competing interests: none declared. Caveat: open design with surrogate physiological endpoints; the abstract does not report a mortality benefit. Study type: randomized trial.